新型线粒体DNA突变所致慢性肾脏病:一例病例报告
本文报告一例由新型线粒体DNA突变导致的慢性肾脏病患者,其肌肉和肾脏均存在线粒体异常,表现为慢性肾小管间质改变和复发性横纹肌溶解。文章探讨了该突变可能通过线粒体损伤驱动慢性肾脏病的机制,并强调在相关肾脏疾病中需考虑潜在的线粒体细胞病变。
要点
- 新型mtDNA突变可导致慢性肾脏病,伴慢性肾小管间质改变和复发性横纹肌溶解。
- 线粒体损伤可启动致病过程,驱动肾脏疾病进展。
- 对相关肾脏疾病应警惕潜在的线粒体细胞病变,其存在比通常认识的更常见。
核心结论
- 新型mtDNA突变患者可发生慢性肾脏病,其机制可能与线粒体损伤驱动的肾小管间质病变有关。
研究设计与样本
- 病例报告:描述一例携带新型mtDNA突变并发生慢性肾脏病的患者。
主要发现
- 患者肌肉和肾脏均显示线粒体异常,肾脏呈慢性肾小管间质改变,并有复发性横纹肌溶解发作。
临床怎么用
- 在相关肾脏疾病中应考虑潜在线粒体细胞病变,因其存在比通常认识的更常见。
局限性
- 本文为单例病例报告,线粒体改变在人类肾脏病中的贡献程度尚不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In human kidney disease, mitochondrial ultrastructural damage has long been recognized. Although the extent to which such mitochondrial changes contribute to human kidney disease is uncertain, experimental studies clearly demonstrate that mitochondrial damage can instigate pathogenetic processes that drive ongoing kidney disease. Clinical credence for this experimentally based hypothesis is provided by the development of kidney disease in patients with primary mitochondrial disorders. In this regard, substantial interest surrounds the occurrence of kidney disease in primary mitochondrial cytopathies, a heterogeneous group of conditions in which mutations in mitochondrial DNA (mtDNA) or nuclear DNA impair the functionality of components of the mitochondrial respiratory chain. We describe a novel mtDNA mutation in a patient who developed chronic kidney disease. The patient exhibited mitochondrial abnormalities in both muscle and kidney, chronic tubulointerstitial changes, and recurrent episodes of rhabdomyolysis. We outline mechanisms that may underlie the occurrence of chronic kidney disease in the setting of this novel mtDNA mutation. We also underscore the need to consider in relevant kidney diseases the presence of an underlying mitochondrial cytopathy because the latter more commonly exists than is generally recognized.
引用
- Fervenza FC, Gavrilova RH, Nasr SH, et al. CKD Due to a Novel Mitochondrial DNA Mutation: A Case Report. Am J Kidney Dis. 2018. PMID: 30309714. doi:10.1053/j.ajkd.2018.06.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。